MX392203B - Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico - Google Patents

Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico

Info

Publication number
MX392203B
MX392203B MX2020005113A MX2020005113A MX392203B MX 392203 B MX392203 B MX 392203B MX 2020005113 A MX2020005113 A MX 2020005113A MX 2020005113 A MX2020005113 A MX 2020005113A MX 392203 B MX392203 B MX 392203B
Authority
MX
Mexico
Prior art keywords
tetrahydrospiro
methoxypyridin
piperidine
oxo
carbonyl
Prior art date
Application number
MX2020005113A
Other languages
English (en)
Other versions
MX2020005113A (es
Inventor
Dilinie Fernando
Kristin Wiglesworth
Shawn M Lacasse
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2020005113A publication Critical patent/MX2020005113A/es
Publication of MX392203B publication Critical patent/MX392203B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona la sal tris de ácido 4-(4-(1-isopropil-7-oxo-1,4,6,7- tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico como un anhidro cristalino o trihidrato; así como polimorfos, composiciones 5 farmacéuticas, formas de dosificación y su uso en el tratamiento de enfermedades, afecciones o trastornos modulados por la inhibición de una(s) enzima(s) de acetil-CoA carboxilasa (ACC) en un animal.
MX2020005113A 2017-11-21 2018-11-14 Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico MX392203B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589256P 2017-11-21 2017-11-21
PCT/IB2018/058966 WO2019102311A1 (en) 2017-11-21 2018-11-14 Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid

Publications (2)

Publication Number Publication Date
MX2020005113A MX2020005113A (es) 2022-05-11
MX392203B true MX392203B (es) 2025-03-21

Family

ID=64559730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005113A MX392203B (es) 2017-11-21 2018-11-14 Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico

Country Status (22)

Country Link
US (1) US11325909B2 (es)
EP (1) EP3713942B8 (es)
JP (1) JP7237082B2 (es)
KR (1) KR102395451B1 (es)
CN (1) CN111406056B (es)
AU (1) AU2018372109B2 (es)
BR (1) BR112020008413A2 (es)
CA (1) CA3082867C (es)
DK (1) DK3713942T3 (es)
ES (1) ES2942463T3 (es)
FI (1) FI3713942T3 (es)
HU (1) HUE061885T2 (es)
IL (2) IL274820B2 (es)
MX (1) MX392203B (es)
PL (1) PL3713942T3 (es)
PT (1) PT3713942T (es)
RU (1) RU2020116458A (es)
SG (1) SG11202003600QA (es)
SI (1) SI3713942T1 (es)
TW (1) TWI703143B (es)
WO (1) WO2019102311A1 (es)
ZA (1) ZA202002566B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7161605B2 (ja) 2018-08-31 2022-10-26 ファイザー・インク Nash/nafldおよび関連疾患の治療のための組合せ
CA3140972C (en) * 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Nafld/nashおよび関連疾患の処置のための組合せ
CN117940422A (zh) 2021-08-31 2024-04-26 辉瑞大药厂 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸,1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
CH702192A1 (de) 2009-11-04 2011-05-13 New Dent Ag Keramisches Implantat.
UA102336C2 (uk) 2009-11-10 2013-06-25 Пфайзер Інк. N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
DK2621493T3 (en) 2010-09-30 2016-10-24 Pfizer N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS
CN103189377B (zh) 2010-10-29 2015-02-25 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
EA022375B1 (ru) * 2011-04-22 2015-12-30 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ

Also Published As

Publication number Publication date
BR112020008413A2 (pt) 2020-10-06
AU2018372109A1 (en) 2020-05-07
KR102395451B1 (ko) 2022-05-09
ZA202002566B (en) 2023-09-27
KR20200074169A (ko) 2020-06-24
FI3713942T3 (fi) 2023-05-04
TW201932466A (zh) 2019-08-16
IL274820A (en) 2020-07-30
CA3082867A1 (en) 2019-05-31
TWI703143B (zh) 2020-09-01
ES2942463T3 (es) 2023-06-01
JP2021504442A (ja) 2021-02-15
EP3713942B1 (en) 2023-03-08
RU2020116458A (ru) 2021-12-23
CA3082867C (en) 2022-05-10
CN111406056A (zh) 2020-07-10
EP3713942A1 (en) 2020-09-30
RU2020116458A3 (es) 2021-12-23
MX2020005113A (es) 2022-05-11
US11325909B2 (en) 2022-05-10
US20200354362A1 (en) 2020-11-12
WO2019102311A1 (en) 2019-05-31
PT3713942T (pt) 2023-04-17
IL274820B2 (en) 2024-11-01
DK3713942T3 (da) 2023-04-03
CN111406056B (zh) 2023-02-28
EP3713942B8 (en) 2023-04-12
IL274820B1 (en) 2024-07-01
IL313710A (en) 2024-08-01
SI3713942T1 (sl) 2023-06-30
JP7237082B2 (ja) 2023-03-10
SG11202003600QA (en) 2020-06-29
HUE061885T2 (hu) 2023-08-28
PL3713942T3 (pl) 2023-05-29
AU2018372109B2 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
MX2020005113A (es) Sal cristalina de 2-amino-2-(hidroximetil)propano-1,3-diol de acido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidrospiro[indazol-5,4' -piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico.
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
UY37845A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CL2022000763A1 (es) Derivados de 2-isoindol-1,3,4-oxadiazol útiles como inhibidores de la histona desacetilasa 6 (hdac6)
CY1118016T1 (el) ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ
BR112016026809A2 (pt) compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
UY37363A (es) Sulfonilureas y compuestos relacionados y sus usos
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
CL2017001686A1 (es) 5-fluoro-4-imino-3-(alquil/alquil sustituido)-1-(arilsulfonil)-3,4-dihidropirimidin-2(1h)-ona como tratamiento de semillas.
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO7170153A2 (es) Composición herbicida que comprende como ingrediente activo, un compuesto de uracilo
CR20170092A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
UY37164A (es) Derivados de piridino-/pirimidino-piridino herbicidas
AR106257A1 (es) 3-fenilpirrolidina-2,4-dionas sustituidas con alquinilo y su uso como herbicidas
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
UY37163A (es) Derivados de piridino-/pirimidino-piridino herbicidas
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
MX389589B (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.